Health Policy Simulation
Our work in Health Policy Simulation
-
Innovation in Heart Failure Treatment: Life Expectancy, Disability, and Health Disparities
Using the Future Elderly Model, researchers evaluated the potential health benefits from innovation in heart failure treatment.
Categorized in -
Raising the Social Security Entitlement Age: Implications for the Productive Activities of Older Adults
Researchers evaluated the economic impact of older adults and the value of their unpaid, productive activities and financial gifts to family.
Categorized in -
Lifetime Consequences of Early-Life and Midlife Access to Health Insurance: A Review
The researchers reviewed 112 experimental or quasi-experimental studies on the effects of health insurance prior to people becoming eligible for Medicare on a broad set of outcomes.
Categorized in -
Projecting Diabetes Prevalence among Mexicans Aged 50 Years and Older: The Future Elderly Model-Mexico (FEM-Mexico)
This study estimated the future prevalence of diabetes among Mexico’s older adults to assess the current and future health and economic burden of diabetes.
Categorized in -
Using Self Reports or Claims to Assess Disease Prevalence
Patricia St. Clair and her colleagues assess prevalence of diabetes and heart attack in the US elderly population across the most well used data sources for estimation.
Categorized in -
Quantifying the Life-cycle Benefits of a Prototypical Early Childhood Program
Heckman and his colleagues estimate the internal rate of return is 13.7 percent for the high quality early childhood education program analyzed. The associated benefit/cost ratio is 7.3.
Categorized in -
The Lifecycle Benefits of an Influential Early Childhood Program
The Future Americans Model (FAM) was adapted to estimate benefits from an influential early childhood program.
Categorized in -
How the Growing Gap in Life Expectancy May Affect Retirement Benefits and Reforms
Growing gap in life expectancy by income increases gap in lifetime retirement benefits including Medicare by $130,000
Categorized in -
Alzheimer’s-Preventing Drugs May Already Exist – We Just Can’t Test Them
Many people who use statins to fight heart disease seem to be on a slower track for developing Alzheimer’s compared to the rest of the population. Yet multiple hurdles stand in the way for this sort of study.
Categorized in -
The Future of Cures: Investing in Value, Innovation and Access
High-cost drugs can generate even higher societal value when they combat serious disease, which should be accounted for in financing methods and pricing models to encourage medical innovation.
Categorized in